吡咯里西啶生物碱毒性作用研究进展

中国药物警戒 ›› 2019, Vol. 16 ›› Issue (2): 76-80.

• 吡咯里西啶生物碱的发育毒性专栏 • 上一篇下一篇

吡咯里西啶生物碱毒性作用研究进展

孙潇翔, 向娥, 邱帅凯, 汪晖, 郭喻^*

武汉大学基础医学院药理学系,湖北武汉 430071;发育源性疾病湖北省重点实验室,湖北武汉 430071

收稿日期:2019-03-12 修回日期:2019-03-12 出版日期:2019-02-25 发布日期:2019-03-12
作者简介:孙潇翔,男,在读硕士,药理学。

Research Progress on Toxicity of Pyrrolizidine Alkaloids

SUN Xiaoxiang, XIANG E, QIU Shuaikai, WANG Hui, GUO Yu^*

Department of Pharmacology, School of Basic Medical Science, Wuhan University, Hubei Wuhan 430071, China; Hubei Provincial Key Laboratory of Developmentally Originated Disease, Hubei Wuhan 430071, China

Received:2019-03-12 Revised:2019-03-12 Online:2019-02-25 Published:2019-03-12
Contact: *郭喻,女,副教授,发育毒理学。E-mail：guoy@whu.edu.cn
Supported by:
国家自然科学基金（81473290）：吡咯里西啶生物碱致母、胎肝毒性差异及其代谢活化机制; 国家自然科学基金青年项目（30901835）：胎肾上腺CYP3A介导吡咯双环生物碱类发育毒性的代谢损伤机制; 中央高校基本科研业务费专项（2042017Kf1032）：吡咯里西啶生物碱致发育毒性的性别差异及其机制研究

摘要/Abstract

摘要： 吡咯里西啶生物碱（pyrrolizidine alkaloids,PAs）是一类广泛分布于世界各地植物中的天然成分,其中部分种类具有抗肿瘤、抗菌等功效。但大部分PAs的氮氧化物（pyrrolizidine alkaloid N-oxides,PANO）及PAs的代谢活化产物脱氢吡咯里西啶生物碱（dehydropyrrolizidine alkaloids,DHPA）具有多种毒性作用,可导致多脏器损伤、致癌和致发育毒性等。PAs的毒性作用已逐渐引起大众的广泛关注,本研究对近年来PAs的毒性机制、解毒途径及其典型毒性作用的研究进展进行综述。

Abstract: Pyrrolizidine alkaloids (PAs) are a group of natural components which widely distributed in plants all over the world. Some of them have anti-tumor and anti-bacterial effects. However, most PAs exert multiple toxicities after metabolic activation, while toxicities of pyrrolizidine alkaloid N-oxides (PANO) have been reported in recent years. They attack multiple organs, induce carcinomas and cause developmental toxicity. This review updated the research on mechanism and effect of PAs toxicity as well as detoxification during recent years.

Key words: pyrrolizidine alkaloids, metabolic activation, toxicity

中图分类号:

R961

孙潇翔, 向娥, 邱帅凯, 汪晖, 郭喻. 吡咯里西啶生物碱毒性作用研究进展[J]. 中国药物警戒, 2019, 16(2): 76-80.

SUN Xiaoxiang, XIANG E, QIU Shuaikai, WANG Hui, GUO Yu. Research Progress on Toxicity of Pyrrolizidine Alkaloids[J]. Chinese Journal of Pharmacovigilance, 2019, 16(2): 76-80.

参考文献

[1] Li Y H, Tai W C, Xue J Y, et al.Proteomic study of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome in rats[J]. Chem Res Toxicol, 2015, 28(9): 1715-1727.
[2] Jia Z J, Takayama H, Futamura Y, et al.Catalytic Enantioselective Synthesis of a Pyrrolizidine-Alkaloid-Inspired Compound Collection with Antiplasmodial Activity[J]. J Org Chem, 2018, 83(13): 7033-7041.
[3] Yang M, Ruan J, Gao H, et al.First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans[J]. Archives of Toxicology, 2017,(4): 1-13.
[4] Huang Z, Chen M, Zhang J, et al.Integrative analysis of hepatic microRNA and mRNA to identify potential biological pathways associated with monocrotaline-induced liver injury in mice[J]. Toxicol Appl Pharmacol, 2017, 333: 35-42.
[5] The China Pharmacopoeia Committee. Pharmacopoeia of the People's Republic of China(in Chinese)[S]. 2015ed.Beijing: China Medical Science Press, 2015
[6] Ma C, Liu Y, Zhu L, et al.Determination and regulation of hepatotoxic pyrrolizidine alkaloids in food: A critical review of recent research[J]. Food Chem Toxicol, 2018, 119:50-60.
[7] World Health Organisation.International Programme on Chemical Safety Pyrrolizidine Alkaloids Health and Safety Guide No. 26[s]. Geneva:1989.
[8] Li N, Xia Q, Ruan J, et al.Hepatotoxicity and tumorigenicity induced by metabolic activation of pyrrolizidine alkaloids in herbs[J]. Curr Drug Metab, 2011, 12(9): 823-834.
[9] Ruan J, Liao C, Ye Y, et al.Lack of metabolic activation and predominant formation of an excreted metabolite of nontoxic platynecine-type pyrrolizidine alkaloids[J]. Chem Res Toxicol, 2014, 27(1): 7-16.
[10] Zhang W, Huai W, Zhang Y, et al.Ultra-Performance Liquid Chromatography Hyphenated with Quadrupole-Orbitrap Mass Spectrometry for Simultaneous Determination of Necine-Core-Structure Pyrrolizidine Alkaloids in Crotalaria sessiliflora L. without all Corresponding Standards[J]. Phytochem Anal, 2017, 28(5): 365-373.
[11] Kolrep F, Numata J, Kneuer C, et al.In vitro biotransformation of pyrrolizidine alkaloids in different species. Part I: Microsomal degradation[J]. Arch Toxicol, 2018, 92(3): 1089-1097.
[12] Moreira R, Pereira D M, Valentao P, et al.Pyrrolizidine Alkaloids: Chemistry, Pharmacology, Toxicology and Food Safety[J]. Int J Mol Sci, 2018, 19(6).
[13] Prakash A S, Pereira T N, Reilly P E, et al.Pyrrolizidine alkaloids in human diet[J]. Mutat Res, 1999, 443(1-2): 53-67.
[14] Tu M, Li L, Lei H, et al.Involvement of organic cation transporter 1 and CYP3A4 in retrorsine-induced toxicity[J]. Toxicology, 2014, 322:34-42.
[15] Hessel S, Gottschalk C, Schumann D, et al.Structure-activity relationship in the passage of different pyrrolizidine alkaloids through the gastrointestinal barrier: ABCB1 excretes heliotrine and echimidine[J]. Molecular Nutrition & Food Research, 2014, 58(5): 995-1004.
[16] Habs M, Binder K, Krauss S, et al.A Balanced Risk-Benefit Analysis to Determine Human Risks Associated with Pyrrolizidine Alkaloids(PA)-The Case of Herbal Medicinal Products Containing St. John's Wort Extracts (SJW)[J]. Nutrients, 2018, 10(7).
[17] Yang M, Ruan J, Fu P P, et al.Cytotoxicity of pyrrolizidine alkaloid in human hepatic parenchymal and sinusoidal endothelial cells: Firm evidence for the reactive metabolites mediated pyrrolizi-dine alkaloid-induced hepatotoxicity[J]. Chem Biol Interact, 2016, 243:119-126.
[18] Ji L, Liu T, Wang Z.Pyrrolizidine alkaloid clivorine induced oxidative injury on primary cultured rat hepatocytes[J]. Hum Exp Toxicol, 2010, 29(4): 303-309.
[19] Ji L, Liu T, Chen Y, et al.Protective mechanisms of N-acetyl-cysteine against pyrrolizidine alkaloid clivorine-induced hepatotoxicity[J]. J Cell Biochem, 2009, 108(2): 424-432.
[20] Ji L, Ma Y, Wang Z, et al.Quercetin prevents pyrrolizidine alkaloid clivorine-induced liver injury in mice by elevating body defense capacity[J]. PLoS One, 2014, 9(6): e98970.
[21] Ahmed L A, Obaid A A, Zaki H F, et al.Naringenin adds to the protective effect of L-arginine in monocrotaline-induced pulmonary hypertension in rats: favorable modulation of oxidative stress, inflammation and nitric oxide[J]. Eur J Pharm Sci, 2014, 62(4):161-170.
[22] Baybutt R C, Rosales C, Brady H, et al.Dietary fish oil protects against lung and liver inflammation and fibrosis in monocrotaline treated rats[J]. Toxicology, 2002, 175(1-3): 1-13.
[23] Yang X, Li W, Sun Y, et al.Comparative Study of Hepatotoxicity of Pyrrolizidine Alkaloids Retrorsine and Monocrotaline[J]. Chem Res Toxicol, 2017, 30(2): 532-539.
[24] Ji L, Chen Y, Liu T, et al.Involvement of Bcl-xL degradation and mitochondrial-mediated apoptotic pathway in pyrrolizidine alkaloids-induced apoptosis in hepatocytes[J]. Toxicol Appl Pharmacol, 2008, 231(3): 393-400.
[25] Xiong A, Yang F, Fang L, et al.Metabolomic and Genomic Evidence for Compromised Bile Acid Homeostasis by Senecionine, a Hepatotoxic Pyrrolizidine Alkaloid[J]. Chemical Research in Toxicology, 2014, 27(8): 775-786.
[26] Pyrrolizidine alkaloids: Pulmonary hypertension in an elderly patient: case report[J]. 2009, 1255: 28.
[27] Dias-neto M, Luísa-neves A, Pinho S, et al. Pathophysiology of Infantile Pulmonary Arterial Hypertension Induced by Monocrotaline[J]. Pediatric Cardiology, 2015, 36(5): 1000-1013.
[28] Huang Z, Liu Z, Luo Q, et al. Glycoprotein 130 Inhibitor Ameliorates Monocrotaline-Induced Pulmonary Hypertension in Rats[J]. Canadian Journal of Cardiology, 2016, 32(11): 1356.e1351-1356.e1310.
[29] Preliasco M, Gardner D, Moraes J, et al.Senecio grisebachii Baker: Pyrrolizidine alkaloids and experimental poisoning in calves[J]. Toxicon, 2017, 133:68-73.
[30] Lakshmanan H, Raman J, Pandian A, et al.Aqueous extract of Senecio candicans DC induce liver and kidney damage in a sub-chronic oral toxicity study in Wistar rats[J]. Regulatory Toxicology & Pharmacology Rtp, 2016, 79:25-34.
[31] Yao J, Li C, Gong L, et al.Hepatic cytochrome P450s play a major role in monocrotaline-induced renal toxicity in mice[J]. Acta Pharmacologica Sinica, 2014, 35(2): 292-300.
[32] Luckert C, Hessel S, Lenze D, et al.Disturbance of gene expression in primary human hepatocytes by hepatotoxic pyrrolizidine alkaloids: A whole genome transcriptome analysis[J]. Toxicology in vitro : an international journal published in association with BIBRA, 2015, 29(7): 1669-1682.
[33] Chen T, Mei N, Fu P P.Genotoxicity of pyrrolizidine alkaloids[J]. J Appl Toxicol, 2010, 30(3): 183-196.
[34] Coulombe R A, Drew G L, Stermitz F R.Pyrrolizidine alkaloids crosslink DNA with actin[J]. Toxicol Appl Pharmacol, 1999, 154(2): 198-202.
[35] Xia Q, Yan J, Chou M W, et al.Formation of DHP-derived DNA adducts from metabolic activation of the prototype heliotridine-type pyrrolizidine alkaloid, heliotrine[J]. Toxicol Lett, 2008, 178(2): 77-82.
[36] Brown A W, Stegelmeier B L, Colegate S M, et al.Heterozygous p53 knockout mouse model for dehydropyrrolizidine alkaloid-induced carcinogenesis[J]. J Appl Toxicol, 2015, 35(12): 1557-1563.
[37] Chou M W, Yan J, Nichols J, et al.Correlation of DNA adduct formation and riddelliine-induced liver tumorigenesis in F344 rats and B6C3F1 mice[J]. Cancer Letters, 2003, 193(2): 119-125.
[38] Roulet M, Laurini R, Rivier L, et al.Hepatic veno-occlusive disease in newborn infant of a woman drinking herbal tea[J]. J Pediatr, 1988, 112(3): 433-436.
[39] Guo Y, Ma Z, Kou H, et al.Synergistic effects of pyrrolizidine alkaloids and lipopolysaccharide on preterm delivery and intrauterine fetal death in mice[J]. Toxicology Letters, 2013, 221(3): 212-218.
[40] Li X, Yang X, Xiang E, et al.Maternal-Fetal Disposition and Metabolism of Retrorsine in Pregnant Rats[J]. Drug Metab Dispos, 2018, 46(4): 422-428.
[41] Sandini T M, Udo m S, Reis-silva T M, et al. Prenatal exposure to integerrimine N-oxide impaired the maternal care and the physical and behavioral development of offspring rats[J]. Int J Dev Neurosci, 2014, 36(36):53-63.
[42] Sandini T M, Udo M S, Reis-silva T M, et al. Prenatal exposure to integerrimine N-oxide enriched butanolic residue from Senecio brasiliensis affects behavior and striatal neurotransmitter levels of rats in adulthood[J]. Int J Dev Neurosci, 2015, 47(Pt B): 157-164.
[43] Papacleovoulou G, Abu-hayyeh S, Nikolopoulou E, et al. Maternal cholestasis during pregnancy programs metabolic disease in offspring[J]. J Clin Invest, 2013, 123(7): 3172-3181.

吡咯里西啶生物碱毒性作用研究进展

Research Progress on Toxicity of Pyrrolizidine Alkaloids

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	李嘉昕, 刘慧敏, 钱文秀, 马宁, 宋丽丽, 李遇伯. 基于中药系统毒理学数据库的中药致肾毒性及药物规律研究[J]. 中国药物警戒, 2024, 21(2): 173-180.
[2]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[3]	左甜甜, 王赵, 郭愿生, 魏锋, 金红宇, 马双成. 基于多元素快速筛查西洋参中毒性元素的非致癌性与致癌性风险评估[J]. 中国药物警戒, 2023, 20(10): 1108-1112.
[4]	曹琳, 冉峥, 侯强, 邱作成, 杨建华. 化铁丸化学成分分析及其防治乳腺增生的潜在机制预测[J]. 中国药物警戒, 2023, 20(10): 1113-1120.
[5]	黄锦坚, 张晓朦, 张冰, 丁雪丽, 杨莹, 林志健. 降尿酸药物的心血管风险信号挖掘及机制研究[J]. 中国药物警戒, 2023, 20(8): 866-871.
[6]	邹东梅, 方芳, 郭轶先, 倪婧, 赵弘, 胡蓉华, 孙婉玲. 体重及美法仑相对剂量与POEMS综合征ASCT预处理不良反应的相关性分析[J]. 中国药物警戒, 2023, 20(8): 911-914.
[7]	左泽平, 田颖颖, 徐意, 姜克武, 杨硕, 杨海润, 张志聪, 曹欣垚, 吴笑如, 王志斌. 金匮肾气丸临床前安全性评价研究[J]. 中国药物警戒, 2023, 20(7): 775-782.
[8]	于乐成, 郝坤艳, 范晔. 中草药肝损伤的临床诊断[J]. 中国药物警戒, 2023, 20(5): 481-488.
[9]	丁子禾, 张彦琼, 林娜. 从脂质代谢途径探讨中药雷公藤“物-效/毒-靶”关联性的研究现状与展望[J]. 中国药物警戒, 2023, 20(5): 489-495.
[10]	罗琼, 李盟, 李光耀, 何彦春, 周祖山, 孙鑫, 刘成海. 635例类风湿性关节炎患者应用雷公藤制剂所致肝损伤的中医证候及联合用药特点[J]. 中国药物警戒, 2023, 20(5): 500-504.
[11]	曹琳, 居博伟, 冉峥, 杨建华, 胡君萍. 肉苁蓉苯乙醇总苷对胆汁淤积型肝病小鼠的预防保护作用[J]. 中国药物警戒, 2023, 20(3): 286-291.
[12]	李盟, 李容容, 刘成海. 中草药引起肝损伤的临床诊治与用药[J]. 中国药物警戒, 2023, 20(2): 127-131.
[13]	于洁, 朱浩翔, 张继明. 疑似千里光类药物致药物性肝损伤1例分析[J]. 中国药物警戒, 2023, 20(2): 136-139.
[14]	翟玉霞, 张孝莹, 门伟婕, 成丽媛, 张玥, 周昆. 黄芪、赤芍配伍补骨脂对大鼠体内补骨脂素和异补骨脂素药代动力学的影响[J]. 中国药物警戒, 2023, 20(2): 152-156.
[15]	胡婧楠, 冯玉, 田义龙, 王鑫国, 牛丽颖. 露水草植物蜕皮甾酮类化学成分及其药理作用研究进展[J]. 中国药物警戒, 2023, 20(2): 231-235.